RESUMEN
Physical activity is undeniably associated with numerous health benefits. However, performance of high intensity and/or high-volume exercise poses a significant physiological challenge to the cardiovascular and respiratory systems, which must undergo several adaptations to meet the increased metabolic demands of the organism. Repeated and prolonged exposure to training leads to long-term cardiac remodeling aimed at optimizing the efficiency of the work performed by the heart during exertion. This article discusses some of the fundamental mechanisms of cardiovascular physiology during exercise including adaptive responses to acute bouts of exercise and longer term structural and functional characteristics of the athlete's heart.
L'exercice physique est indéniablement associé à de nombreux bénéfices pour la santé. La réalisation d'un effort représente un défi physiologique important pour le système cardiovasculaire et respiratoire, qui doivent entreprendre plusieurs adaptations permettant l'augmentation du débit cardiaque afin de palier l'augmentation des demandes métaboliques de l'organisme. L'exposition répétée et prolongée à l'entraînement induit à long terme un remodelage cardiaque optimisant l'efficience du système cardiovasculaire à l'effort. Dans cet article, nous analysons certains des mécanismes de base de la physiologie cardiovasculaire à l'effort, en passant des adaptations survenant lors d'un effort, pour finalement discuter des adaptations structurelles et fonctionnelles qui caractérisent le cÅur d'athlète.
Asunto(s)
Adaptación Fisiológica , Atletas , Ejercicio Físico , Corazón , Humanos , Ejercicio Físico/fisiología , Adaptación Fisiológica/fisiología , Corazón/fisiología , Fenómenos Fisiológicos CardiovascularesRESUMEN
Whole body cryotherapy is mainly performed either by immersion in cold water or in a cryotherapy chamber. Practiced since Antiquity and considered as a «â naturalâ ¼ method, cryotherapy is attracting more and more followers. Beneficial health effects have been described in the literature. However, interpretation of its effects is difficult due to low quality of current studies. Cryotherapy could however be useful in addition to conventional therapies in various pathologies and situations, provided that the risks, contraindications and rules of good practice are known.
La cryothérapie du corps entier se pratique principalement soit par immersion en eau froide, soit en chambre de cryothérapie. Pratiquée depuis l'Antiquité et considérée comme une méthode «â naturelleâ ¼, la cryothérapie tend à attirer de plus en plus d'adeptes. Des effets bénéfiques pour la santé ont été décrits dans la littérature. Néanmoins, l'interprétation de ses effets est difficile en raison de la faible qualité des études actuelles. La cryothérapie pourrait toutefois être utile en complément des thérapies classiques dans diverses pathologies et situations, à condition de connaître les risques, les contre-indications et les règles de bonnes pratiques.
Asunto(s)
Crioterapia/efectos adversos , Crioterapia/métodos , Agua , Crioterapia/instrumentación , HumanosRESUMEN
Immune checkpoint inhibitors (ICI) have revolutionized the field of oncology, by reshaping the prognosis of many cancers and are progressively becoming the standard of care. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), of which cardiovascular irAEs are particularly feared. ICI-induced myocarditis is often a diagnostic challenge because of the vast heterogeneity of clinical presentations, and it is associated with a high mortality rate of around 50%. The present article summarizes the cardiac manifestations, the diagnostic strategy and the therapeutic management of patients with ICI-induced myocarditis used in the treatment of cancer.
Les inhibiteurs de points de contrôle immunitaire (ICI), ou immune checkpoint inhibitors (ICI), ont révolutionné la prise en charge de nombreux cancers en améliorant significativement la survie des patients et en devenant progressivement la norme de soins. Cette efficacité a néanmoins pour prix un taux élevé d'effets indésirables immunomédiés avec un large spectre d'organes touchés. Les toxicités cardiaques, dominées par la myocardite induite par les ICI, sont particulièrement redoutées du fait des difficultés diagnostiques et du risque d'évolution rapidement défavorable associée à une mortalité élevée, de l'ordre de 50â %. Le présent article s'intéresse aux manifestations cardiaques, à la stratégie diagnostique ainsi qu'à la prise en charge des patients présentant une myocardite induite par les ICI utilisés dans le traitement du cancer.
Asunto(s)
Cardiotoxicidad/etiología , Inmunoterapia/efectos adversos , Miocarditis/inducido químicamente , Neoplasias/tratamiento farmacológico , Humanos , Neoplasias/inmunología , Neoplasias/patologíaRESUMEN
Immersion pulmonary edema may occur during scuba diving, snorke-ling or swimming. It is a rare and often recurrent disease, mainly affecting individuals aged over 50 with high blood pressure. However it also occurs in young individuals with a healthy heart. The main symptoms are dyspnea, cough and hemoptysis. The outcome is often favorable under oxygen treatment but deaths are reported. A cardiac and pulmonary assessment is necessary to evaluate the risk of recurrence and possible contraindications to immersion.
L'Ådème pulmonaire d'immersion peut survenir durant une plongée sous-marine, une plongée en apnée ou durant la natation. C'est une pathologie rare, souvent récidivante, touchant principalement les individus âgés de plus de 50 ans et hypertendus mais qui survient également chez des individus jeunes avec un cÅur sain. Les symptômes principaux sont une dyspnée, une toux et des hémoptysies. L'évolution est souvent favorable sous traitement d'oxygène mais des décès sont rapportés. Un bilan cardiologique et pulmonaire est nécessaire pour évaluer le risque de récidive et une éventuelle contre-indication à l'immersion.
Asunto(s)
Buceo , Edema Pulmonar , Humanos , Edema Pulmonar/etiología , Edema Pulmonar/terapiaRESUMEN
INTRODUCTION: Supervised exercise training is among the first-line therapies for patients with peripheral artery disease (PAD). Current recommendations for exercise include guidance focusing on claudication pain, programme and session duration, and frequency. However, no guidance is offered regarding exercise training intensity. This study aims to compare the effects of 12-week-long supervised walking exercise training (high-intensity interval training (HIIT) vs moderate-intensity exercise (MOD)) in patients with chronic symptomatic PAD. METHODS AND ANALYSIS: This study is a monocentric, interventional, non-blinded randomised controlled trial. 60 patients (30 in each group) will be randomly allocated (by using the random permuted blocks) to 12 weeks (three times a week) of HIIT or MOD. For HIIT, exercise sessions will consist of alternating brief high-intensity (≥85% of the peak heart rate (HRpeak)) periods (≤60 s) of work with periods of passive rest. Patients will be asked to complete 1 and then 2 sets of 5-7 (progressing to 10-15×60 s) walking intervals. For the MOD group, exercise training sessions will consist of an alternation of periods of work performed at moderate intensity (≤76% HRpeak) and periods of passive rest. Interventions will be matched by training load. The primary outcome will be the maximal walking distance. Secondary outcomes will include functional performance, functional capacity, heath-related quality of life, self-perceived walking abilities, physical activity and haemodynamic parameters. ETHICS AND DISSEMINATION: The Angiof-HIIT Study was approved by the Human Research Ethics Committee of the Canton de Vaud (study number: 2022-01752). Written consent is mandatory prior to enrolment and randomisation. The results will be disseminated via national and international scientific meetings, scientific peer-reviewed journals and social media. TRIAL REGISTRATION NUMBER: NCT05612945.
Asunto(s)
Entrenamiento de Intervalos de Alta Intensidad , Calidad de Vida , Humanos , Ejercicio Físico/fisiología , Caminata , Claudicación Intermitente , Terapia por Ejercicio/métodos , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Background: Scuba diving has rarely been associated with spontaneous arterial dissection. However, all documented cases have involved the cervicocranial arteries. Case summary: We report the first case of spontaneous coronary artery dissection (SCAD) potentially associated with scuba diving in a 65-year-old female with no medical history or known cardiovascular risk factors. She presented with sudden-onset chest pain during her descent whilst scuba diving on holiday. An initial ECG revealed transient abnormalities, but due to normal initial blood tests, a reassuring echocardiogram, and the resolution of her symptoms, she was discharged from hospital without a clear diagnosis. During her subsequent presentation to our hospital 1 week later, electrocardiographic evidence of an inferior myocardial infarction (MI) was noted, with an echocardiogram revealing regional wall motion abnormalities of the left ventricular inferior wall. Coronary angiography revealed the presence of a SCAD of the posterior left ventricular artery, with cardiac magnetic resonance imaging confirming the presence of an inferior MI. As recommended in the majority of cases of SCAD, this case was managed conservatively with a favorable clinical course. Conclusion: This is the first reported case of SCAD potentially associated with scuba diving. It highlights the importance of considering SCAD in patients presenting with sudden-onset chest pain during physical activity, especially in female patients (including older patients) with no cardiovascular risk factors. Furthermore, it serves as a reminder that symptoms during scuba diving are not always related to decompression illness.
RESUMEN
OBJECTIVES: Previous studies suggest that smokers have a misperception of their 10-year cardiovascular risk. We aimed to compare 10-year cardiovascular risk self-perception and calculated risk among smokers willing to quit and assess the determinants of a possible misperception. DESIGN: Cross-sectional secondary analysis of baseline data from a randomised controlled trial of smoking cessation. PARTICIPANTS: 514 participants, mean age 51.1â years, 46% women, 98% Caucasian. Eligible participants were regular smokers, aged between 40 and 70â years, with a consumption of at least 10 cigarettes per day for at least a year. None of them had experienced cardiovascular disease before. Exclusion criteria comprised a history of myocardial infarction, coronary heart disease, stroke, heart failure, peripheral vascular disease, carotid atherosclerosis or cardiac arrhythmia. Participants with renal or liver failure, psychiatric disorders, substance and alcohol abuse and with smoking cessation therapies were excluded. INTERVENTIONS: Participants were asked to estimate their 10-year cardiovascular risk using a 3-item scale corresponding to high-risk, moderate-risk and low-risk categories. We compared their risk perception with Framingham and Prospective Cardiovascular Munster Study (PROCAM) scores. We used multivariable-adjusted logistic regression models to determine characteristics of participants who underestimate their risk versus those who correctly estimate or overestimate it. RESULTS: Between 38% and 42% of smokers correctly perceived their 10-year cardiovascular risk, and 39-50% overestimated their 10-year cardiovascular risk while 12-19% underestimated it compared with their calculated 10-year cardiovascular risk depending on the score used. Underestimation of 10-year cardiovascular risk was associated with male gender (OR 8.16; CI 3.83 to 17.36), older age (OR 1.06; CI 1.02 to 1.09), and the presence of hyperlipidaemia (OR 2.71; CI 1.47 to 5.01) and diabetes mellitus (OR 13.93; CI 3.83 to 50.66). CONCLUSIONS: Among smokers, misperception of their 10-year cardiovascular risk is common, with one-fifth underestimating it. These findings may help physicians target patients with such characteristics to help them change their health behaviour and adherence to risk-reduction therapy. TRIAL REGISTRATION NUMBER: NCT00548665; Post-results.